The Molecular Diagnostics Technologies Market is projected to register a strong CAGR during the forecast period (2026-2031).
The molecular diagnostics technologies market includes tests and platforms that detect and analyze biological markers in the genome or proteome. Governments and public health agencies are expanding regulatory frameworks to integrate these technologies into routine screening, infectious disease surveillance, and precision medicine initiatives.
The Molecular Diagnostics Technologies Market encompasses the following components that use molecular assays to provide early accurate diagnosis, treatment selection and epidemiological monitoring of infectious, cancerous and inherited disorders; next generation sequencing platforms (NGS), PCR systems (Polymerase Chain Reaction) and Companion Diagnostic Tools. Due to the increase in incidence and prevalence of infectious disease, cancer and inherited disorder testing, there is a growing demand for fast and accurate molecular testing. Regulatory authorities such as the U.S. Food and Drug Administration (FDA) and European Commission’s In Vitro Diagnostic Regulation (IVDR) are enhancing regulatory guidelines for the safety, performance, and clinical validity of molecular tests/devices/platforms. Public Health Agencies, including the World Health Organization (WHO), are emphasizing the importance of molecular testing capacity related to pandemic preparedness and real-time surveillance.
• Tighter Regulatory Oversight with the In Vitro Diagnostic Regulation (IVDR): The European Commission continues implementing all provisions of this Regulation, which requires extensive clinical evidence, post-market surveillance, and performance validation for molecular tests. This is elevating the quality of genetic testing, infectious disease assays, and companion diagnostics through the addition of compliance standards for manufacturers.
• Greater FDA Regulation of Molecular Diagnostic Testing: The FDA is tightening regulations for molecular diagnostics, including next-generation sequencing (NGS) and polymerase chain reaction (PCR) methods. More detailed regulatory guidance is being provided for analytical validity, clinical performance, and software integration, enabling safer commercialization and greater clinical adoption.
• International Focus on Infectious Disease Monitoring: The World Health Organization continues to stress the importance of molecular diagnostics for detecting outbreaks of disease, monitoring for antimicrobial-resistant bacteria, and preparing for future pandemics. An increase in investment for building laboratory infrastructure around the world supports and expands the capacity of molecular diagnostics.
• Rapid Expansion of Precision Medicine: Molecular diagnostics play an essential role in the treatment of cancer and rare diseases. The expansion of companion diagnostics related to targeted therapies allows clinicians to customize their approaches to patient care based on unique genetic characteristics, which results in improved outcomes for patients.
• Increasing Global Burden from Infectious Diseases: More cases of respiratory infections and antimicrobial resistance are being found, as well as more new pathogens. Rapid and very sensitive molecular tests are needed now, because healthcare systems are trying to find an early way of detecting these infections so that they can lower the amount of them and help make treatment outcomes better. This can also help facilitate a steady use of the PCR and sequencing platforms.
• Increasing Cancer Cases and Personalised Medicine/Precision Oncology: Also, the total number of cancer cases continues to increase on a global scale. As such, the need for biomarker based testing should also increase. Molecular diagnostics help provide information about genetic mutations, tumor characteristics and therapy options. As the number of targeted therapies increases, the need for companion diagnostics will be very important to the day-to-day practices of oncologists.
• Growth of Personalized Medicine: The overall trend is for healthcare providers to start providing more individualised treatments/therapies for their patients. Molecular diagnostic tests enable physicians to better identify the genetic predisposition of patients, determine how the disease will progress and how a patient will respond to a particular medication. The current transition from traditional care to personalized/precise care is driving more demand for genomic and molecular diagnostic technologies.
• Technology Developments in Molecular Testing: PCR and Next Generation Sequencing: Improvements in the sensitivity of the molecular diagnostics tests, as well as turnaround time, automation, and lower test costs have resulted in greater accessibility to the use of molecular diagnostics. Along with these technological improvements, increased automation and broader throughput and scalability for both Next Generation Sequencing and real time PCR systems will continue to make these types of diagnostic tests available to more and more patients all over the world.
• While the market for molecular diagnostics technologies will grow from strong clinical demand, the industry faces many operational/economic challenges. Manufacturers may produce high cost equipment, expensive reagents, and limited laboratory infrastructure, thus creating barriers to entry for laboratories in developing countries with limited resources. Additionally, the shortage in qualified staff to support the laboratory will also be a challenge as the test may be performed improperly or results will not be able to be repeated reliably and accurately. Also, as reimbursement policies vary by healthcare provider, the lack of standardisation among manufacturers, quality control measures, and other testing protocols can negatively impact the utilisation of diagnostic technologies. Standardisation of testing protocols and quality assurance will be key, especially for advanced molecular tests such as complex genomic sequencing. At the same time, opportunities are expanding rapidly. Growing demand for early disease detection, especially in oncology and infectious diseases, continues to drive testing volumes. Advances in automation and integrated sample to answer systems are reducing turnaround times and improving laboratory efficiency. Expansion of personalised medicine is increasing the need for companion diagnostics and biomarker identification. Emerging markets are investing in laboratory modernisation and decentralized testing infrastructure, creating long term growth potential. Integration of molecular platforms with digital health systems and data analytics is further enhancing clinical decision support and population level disease monitoring.
• November?2025: Thermo Fisher Scientific announced that its EXENT Analyser and Immunoglobulin Isotypes (GAM) Assay received 510(k) clearance from the U.S. Food and Drug Administration as an automated molecular diagnostic platform designed to assist in the detection and identification of multiple myeloma and related plasma cell disorders. The system offers enhanced sensitivity for measuring M-proteins at low concentrations and automates workflows to provide clear, reliable results that support early and confident clinical diagnoses. This clearance strengthens Thermo Fisher’s position in advanced molecular diagnostics and exemplifies how machine learning and automated analysis tools are being integrated into clinical laboratories to support oncologic testing and disease monitoring.
The market is segmented by product type, technology, application and geography.
The largest and most recurring revenue segment is made up of reagents & kits. Examples of reagent types are assay kits, primers, probes, enzymes, buffers, and consumables needed for PCR, sequencing, and/or hybridization workflows used by laboratories for routine infectious disease testing, oncology panel testing, and genetic screening. Laboratories operate from a consistently available supply of reagents in order to conduct high test volume, repeat purchase cycles of these tests. This is why this product family can provide major stable growth for suppliers.
Next Generation Sequencing (NGS) allows for large scale genomic analysis with high throughput and accuracy. NGS is being used for tumor profiling, detection of rare diseases, and determining hereditary risk factors. Compared to traditional sequencing techniques, NGS allows multiple gene analysis to occur simultaneously, thus expanding the depth of diagnostic profiling and supporting precision medicine initiatives. With the cost of sequencing decreasing as automation increases, more clinical laboratories are beginning to become involved.
Oncology is one of the largest applications/areas of growth in molecular diagnostics due to the growing demand for characterizing tumors and identifying biomarkers. Molecular diagnostics are used to identify genetic mutations to determine the correct targeted therapy, as well as monitor patient response to treatment. Companion diagnostics associated with specific cancer therapies are becoming more widely used as part of the overall cancer treatment pathway. The continual increase of cancer occurrences around the globe drives further demand for molecular testing in oncology.
The healthcare infrastructure in North America is the most advanced in the world, plus there are a high number of tests performed on an annual basis. The region was also one of the first to introduce advanced molecular technologies. During the last several years, the use of PCR, next generation sequencing and high-throughput technologies for cancer screening, monitoring of infectious diseases and transplant testing has become very common. There are also digital workflows being used by hospitals and reference laboratories to integrate communications, manage data and improve reporting efficiency. As a result of high levels of participation in clinical research, new technologies such as precision medicine are being developed rapidly, which are causing many clinicians to invest in upgrading their laboratories. Therefore, North America is considered a leader in clinical implementation and the continuous development of new technologies.
South America is an emerging market with increasing focus on molecular diagnostics. Brazil, Argentina, Chile, and Colombia are strengthening clinical laboratory networks and expanding testing capacity for diseases such as HIV, tuberculosis, and cancer. Public health initiatives and screening programs are driving adoption of PCR and sequencing platforms. Collaboration with international partners and improvement in reimbursement frameworks are supporting broader use of advanced assays. Continued healthcare investment and rising awareness of early diagnosis benefits contribute to regional growth.
In Europe, expansion of public health screening programmes and increasing demand for personalised healthcare are driving demand. Public health systems across Europe are improving laboratory networks and diagnostic capacity for use in diagnosing cancer and chronic infectious diseases. In addition to the widespread use of molecular tests in the hospital setting, cancer and genetic disorders are diagnosed by using advanced assays in tertiary care centres and hospitals that participate in cross-border collaborations aligned with harmonised clinical guidelines. The drive to improve the quality of care and lessen the time it takes to provide results is further fuelling the demand for improvements in Europe
The Middle East and Africa region has not yet experienced the widespread adoption of advanced laboratory technology as many other regions of the world, but continues to experience growth as healthcare organisations are modernizing their healthcare delivery systems. Some nations, such as the United Arab Emirates, Saudi Arabia and South Africa, are expanding laboratory and testing services and adopting molecular technologies for use with cancer and infectious disease diagnostics. The use of telemedicine and remote laboratory support can assist with filling gaps in staffing within the healthcare system. Ongoing investment into energy-efficient health care systems continues to result in the development of advanced diagnostic testing methods; however, due mainly to resource constraints and infrastructure limitations, the use of advanced testing products will continue to be limited in the developing areas of the Middle East and Africa.
Asia Pacific has seen rapid growth in healthcare expenditures and advances in diagnostic capabilities. The large populations in Asia, especially China, India, Japan, South Korea, and throughout the Southeast Asian region, create substantial demand for testing. By establishing laboratory infrastructure and forming technology-transfer agreements with traditional global vendors, many emerging countries are leveraging these molecular platforms. In addition, the significant push by various countries to prepare for disease outbreaks and develop more widespread screening programs for various cancers and infectious diseases will add to the continued growth of the market. The collaboration between public and private entities will continue to improve clinical capabilities and provide more opportunities for patients to access molecular diagnostic testing.
• Roche Diagnostics
• Thermo Fisher Scientific
• Abbott Laboratories
• Danaher Corporation
• Qiagen
• Bio-Rad Laboratories
• Hologic
• Agilent Technologies
• Illumina
• Siemens Healthineers
The industry is in the process of consolidation as players target the provision of " Molecular Diagnostics Technologies Market” toolchains.
Roche Diagnostics is a globally recognized leader in molecular diagnostic products, tools, and technologies. Within its product offerings you will find real-time PCR systems, high-throughput testing solutions, and companion diagnostics used for oncological, infectious diseases, and genetic testing. Its diagnostic technology facilitates laboratory automation and collaboration through integration with laboratory information systems, allowing for optimal workflows and data management. Roche also manufactures multiplex assays to enable the simultaneous detection of various pathogens. Furthermore, Roche's continuous investments in new technologies including next-generation sequencing and biomarker discovery are helping to solidify its role in the field of precision medicine. The breadth of Roche's portfolio and its global reach establish it as one of the leading diagnostic companies, helping to make it an essential component of clinical and reference labs.
Thermo Fisher Scientific is a manufacturer and distributor of many types of molecular diagnostic technologies, including PCR technology, next-generation sequencing technology, reagents, and bioinformatics software. Thermo Fisher's Applied Biosystems brand manufactures and sells products that relate to genetic analysis, infectious disease identification, and research purposes. Additionally, Thermo Fisher's platforms provide high-throughput workflows, allowing labs to increase their testing capacity. Thermo Fisher also offers package solutions for integrated service/support to help labs achieve optimal assay performance and compliance. Thermo Fisher is well-known for its strong commitment to research and development in order to support ongoing innovation in molecular testing and laboratory automation, positioning it to be a critical partner for clinical and research labs globally.